ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Favorable Outcome of Pathologic Downstaging by Locoregional Treatment for Hepatocellular Carcinoma in Liver Transplantation

D. Kim, J. Lee, S. Kim, K. In, D. Joo, S. Kim, M. Kim

Severance hospital, Seoul, Korea, Republic of

Meeting: 2019 American Transplant Congress

Abstract number: D121

Keywords: Hepatocellular carcinoma, Liver transplantation

Session Information

Session Name: Poster Session D: Liver: Hepatocellular Carcinoma and Other Malignancies

Session Type: Poster Session

Date: Tuesday, June 4, 2019

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Hall C & D

*Purpose: There was no distinct guideline how to take into account the effect of pretransplant locoregional treatment (LRT) in hepatocellular carcinoma (HCC) staging system. The aim of this study was to investigate the prognosis of pathologic downstaging (PDS) by the elimination of total necrosis after liver transplantation.

*Methods: We conducted a study of 326 HCC patients underwent liver transplantation between September 2005 and December 2016.

*Results: Two hundred twenty-two patients received pretransplant LRT and 102 patients did not. Among the former group, 74 (33.0%) achieved PDS while 150 (67.0%) showed unchanged T stage after the elimination of total necrosis. Five-year HCC recurrent free survival (RFS) of PDS group (85.1%) was similar with no LRT group (88.8%) but higher than non-PDS group (68.9%; P<0.001). When compared according to the adjusted T stage and PDS status, PDS T1 (82.4%) showed similar 5 year RFS with non-PDS T1(86.5%). Non-PDS T2 cancers had worse outcome regardless of MC (P=0.982) or UCSF criteria (0.466). When preoperative examination, less than 1 viable tumor, less than 1cm of tumor size and less than 20 ng/mL of serum alpha fetoprotein were associated with PDS.

*Conclusions: Current study showed that PDS by LRT was associated with favorable outcome in HCC patients after liver transplantation.

 border=

 border=

 border=

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Kim D, Lee J, Kim S, In K, Joo D, Kim S, Kim M. Favorable Outcome of Pathologic Downstaging by Locoregional Treatment for Hepatocellular Carcinoma in Liver Transplantation [abstract]. Am J Transplant. 2019; 19 (suppl 3). https://atcmeetingabstracts.com/abstract/favorable-outcome-of-pathologic-downstaging-by-locoregional-treatment-for-hepatocellular-carcinoma-in-liver-transplantation/. Accessed May 18, 2025.

« Back to 2019 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences